查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
高血钾症市场 - 全球及区域 - 分析与预测（2025-2035）
市场调查报告书
商品编码
1759278

高血钾症市场 - 全球及区域 - 分析与预测（2025-2035）

Hyperkalemia Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5个工作天内

价格

高血钾症是一种以血液中钾含量升高为特征的疾病。

钾是人体必需的电解质，有助于调节重要的身体功能，包括神经传递、肌肉收缩和体液平衡。但是，如果钾水平过高，则会导致严重的健康问题，尤其会对心臟产生影响。高血钾最常见的原因是肾功能受损，因为肾臟负责从血液中过滤多余的钾。慢性肾臟病(CKD)、心臟衰竭和糖尿病等疾病会降低肾功能并增加高血钾的风险。使用某些可升高钾水平的药物也可能导致高血钾症，例如 RAAS 抑制剂（ACE 抑制剂、ARB）和保钾利尿剂。高血钾的症状包括肌肉无力、疲劳、心律不整，严重的情况下心臟麻痹。需要立即治疗以控制病情并预防危及生命的併发症。

高血钾市场的主要驱动因素之一是慢性肾臟病(CKD) 盛行率的上升。随着全球人口老化，CKD 盛行率也随之上升，增加了高血钾的风险。 CKD 会导致肾功能逐渐衰退，削弱肾臟过滤并排出体内过量钾的能力。这会导致钾在血液中积聚，引发高血钾症。此外，CKD 患者通常使用 RAAS 抑制剂（例如 ACE 抑制剂、ARB 和醛固酮拮抗剂）来控制病情，而这会进一步升高血钾水平。随着全球 CKD 患者数量的增加，对有效治疗高血钾症的治疗需求显着增加，这推动了市场的成长。此外，心臟衰竭和糖尿病盛行率的上升（这些也是高血钾的诱因）也进一步推动了该市场的成长。

儘管高血钾市场正在成长，但仍有若干挑战阻碍其发展。主要挑战之一是治疗费用高昂，尤其是像 Veltassa（patiromer）和 Lokelma（环硅酸锆钠）等钾粘合剂这样的较新治疗方法。这些疗法费用高昂，难以取得，尤其是对于低收入地区和医疗保险有限的患者。慢性肾臟病(CKD) 和心臟衰竭等慢性病的持续治疗费用给医疗保健系统和患者带来了沉重的经济负担，降低了这些治疗方法的整体应用率。此外，一些降钾药物的副作用，如胃肠不适（如便秘、腹泻、腹痛），会影响患者的依从性并影响治疗方法的有效性。儘管对有效解决方案的需求日益增长，但这些因素阻碍了高血钾管理策略的广泛实施。

全球高血钾市场竞争激烈，多家主要企业推动创新和市场成长。赛诺菲、Ardelyx、阿斯特捷利康、Vifor Pharma 和礼来公司等公司处于开发和提供高血钾治疗方法的前沿。赛诺菲的 Veltassa（patiromer）在治疗慢性高钾血症方面发挥关键作用，尤其是对于患有慢性肾臟病(CKD) 和心臟衰竭的患者。 Ardelyx 拥有创新的高血钾治疗药物 Tenapanor，而Astra Zeneca提供 Lokelma（环硅酸锆钠），这是一种口服钾粘合剂，对急性和慢性高钾血症均有效。礼来公司也持续为市场提供针对肾臟病和心臟衰竭等相关疾病的广泛治疗组合。这些公司正在努力扩大治疗选择的管道，并开发新的治疗方法，以满足全球 CKD 和心臟衰竭发病率上升以及人口老龄化导致高钾血症患者数量不断增加所带来的日益增长的需求。

市场区隔

细分一：按地区

  • 北美洲
  • 欧洲
  • 亚太地区

全球高血钾市场正经历重大变革时期，其驱动力源自于重塑治疗和管理策略的新兴趋势。推动这项变革的关键趋势之一是对创新钾结合疗法的日益关注，例如 Veltassa（帕替罗莫）和 Lokelma（环硅酸锆钠），这些疗法为慢性和急性高钾血症的治疗提供了更有效、更安全的解决方案。这些新疗法旨在应对日益增长的高血钾盛行率，尤其是在患有慢性肾臟病(CKD)、心臟衰竭以及服用可升高钾水平的 RAAS 抑制剂的患者中。

另一个新兴趋势是个人化医疗的兴起，旨在根据患者的特定医疗状况和遗传因素，为其量身定制治疗方案。这种方法可以提高治疗效果，改善患者预后。此外，数位医疗工具和远端患者监护的日益普及，使医疗保健提供者能够即时追踪患者钾水平，从而改善高血钾的管理并减少住院治疗。随着各公司不断创新，并提高高血钾治疗的可近性，尤其是在需求旺盛的未开发地区，这一趋势有望推动市场持续成长。

本报告研究了全球高血钾市场，并概述了市场以及区域趋势和公司概况。

目录

执行摘要

第一章全球高血钾市场：产业展望

  • 介绍
  • 市场趋势
  • 法律规范
  • 流行病学分析
  • 临床试验分析
  • 市场动态

2. 2023-2035 年全球高血钾症市场（按地区）

  • 北美洲
  • 欧洲
  • 亚太地区

3. 全球高血钾市场：竞争格局与公司概况

  • 关键策略和发展
    • 合併与收购
    • 协同活动
    • 业务扩展和资金筹措
    • 产品发布和核准
    • 其他活动
  • 公司简介
    • Sanofi
    • Ardelyx
    • AstraZeneca
    • Vifor Pharma (Zeria Pharmaceutical)
    • Eli Lilly and Company
    • Novo Nordisk
    • Zynteglo (Bluebird Bio)
    • Novartis AG

第四章调查方法

Product Code: BHL3074SA

Global Hyperkalemia Market, Analysis and Forecast: 2025-2035

Hyperkalemia is a medical condition characterized by elevated levels of potassium in the blood. Potassium is an essential electrolyte that helps regulate important bodily functions, including nerve transmission, muscle contraction, and fluid balance. However, when potassium levels become too high, it can lead to serious health issues, particularly affecting the heart. Hyperkalemia is most caused by kidney dysfunction, as the kidneys are responsible for filtering excess potassium from the blood. Conditions like chronic kidney disease (CKD), heart failure, and diabetes can impair kidney function and increase the risk of hyperkalemia. It can also result from the use of certain medications like RAAS inhibitors (ACE inhibitors, ARBs) or potassium-sparing diuretics, which may elevate potassium levels. Symptoms of hyperkalemia include muscle weakness, fatigue, irregular heartbeats, and in severe cases, cardiac arrest. Immediate treatment is necessary to manage the condition and prevent life-threatening complications.

One of the key drivers of the Hyperkalemia market is the rising prevalence of chronic kidney disease (CKD). As the global population ages, the incidence of CKD increases, which in turn raises the risk of hyperkalemia. CKD leads to a gradual decline in kidney function, impairing the kidneys' ability to filter and excrete excess potassium from the body. This results in an accumulation of potassium in the bloodstream, causing hyperkalemia. Moreover, CKD patients are often treated with RAAS inhibitors (such as ACE inhibitors, ARBs, and aldosterone antagonists) to manage their condition, which can further increase potassium levels. With the growing number of CKD patients worldwide, there is a significant rise in the demand for treatments that effectively manage hyperkalemia, driving market growth. Additionally, the rising prevalence of heart failure and diabetes, conditions that also contribute to hyperkalemia, further supports this market growth.

Despite the growth of the Hyperkalemia market, several challenges continue to hinder its progress. One of the primary challenges is the high cost of treatment, particularly for newer therapies such as potassium binders like Veltassa (patiromer) and Lokelma (sodium zirconium cyclosilicate). These treatments can be expensive, making them less accessible, especially in low-income regions or for patients with limited healthcare coverage. The cost of ongoing treatment for chronic conditions like chronic kidney disease (CKD) and heart failure can place a significant financial burden on healthcare systems and patients, reducing the overall adoption of these therapies. Additionally, the side effects associated with some potassium-lowering medications, such as gastrointestinal discomfort (e.g., constipation, diarrhea, and abdominal pain), can affect patient compliance and impact the effectiveness of treatment regimens. These factors contribute to barriers in the broader implementation of hyperkalemia management strategies, despite the rising demand for effective solutions.

The global Hyperkalemia market is highly competitive, with several leading companies driving innovation and market growth. Companies such as Sanofi, Ardelyx, AstraZeneca, Vifor Pharma, and Eli Lilly and Company are at the forefront of developing and offering treatments for hyperkalemia. Sanofi, with its Veltassa (patiromer), has been a significant player in managing chronic hyperkalemia, especially in patients with chronic kidney disease (CKD) and heart failure. Ardelyx is innovating with its drug Tenapanor, designed to treat hyperkalemia, while AstraZeneca offers Lokelma (sodium zirconium cyclosilicate), an effective oral potassium binder for both acute and chronic hyperkalemia. Vifor Pharma, in partnership with Zeria Pharmaceutical, provides essential therapies for patients with renal diseases, while Eli Lilly and Company continues to contribute to the market with its broad portfolio of treatments for related conditions like kidney disease and heart failure. These companies are not only advancing new therapies but are also working to expand access to treatment options, meeting the increasing demand driven by rising cases of hyperkalemia due to the global increase in CKD, heart failure, and an aging population.

Market Segmentation:

Segmentation 1: by Region

  • North America
  • Europe
  • Asia-Pacific

The global Hyperkalemia market is undergoing significant transformation, fueled by emerging trends that are reshaping the landscape of treatment and management strategies. One of the key trends driving this change is the increased focus on innovative potassium-binding therapies, such as Veltassa (patiromer) and Lokelma (sodium zirconium cyclosilicate), which offer more effective and safer solutions for managing both chronic and acute hyperkalemia. These newer treatments are designed to address the growing prevalence of hyperkalemia, particularly in patients with chronic kidney disease (CKD), heart failure, and those on RAAS inhibitors that increase potassium levels.

Another emerging trend is the rise of personalized medicine, which aims to tailor treatment plans to individual patient needs based on specific conditions and genetic factors. This approach enhances treatment efficacy and improves patient outcomes. Additionally, there is an increased emphasis on digital health tools and remote patient monitoring, allowing healthcare providers to track potassium levels in real-time, thereby improving the management of hyperkalemia and reducing hospitalizations. With these trends, the market is poised for continued growth as companies innovate and improve accessibility to hyperkalemia treatments, particularly in underserved regions with rising healthcare demands.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Hyperkalemia Market: Industry Outlook

  • 1.1 Introduction
  • 1.2 Market Trends
  • 1.3 Regulatory Framework
  • 1.4 Epidemiology Analysis
  • 1.5 Clinical Trial Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Impact Analysis
    • 1.6.2 Market Drivers
    • 1.6.3 Market Challenges
    • 1.6.4 Market Opportunities

2. Global Hyperkalemia Market (Region), ($Billion), 2023-2035

  • 2.1 North America
    • 2.1.1 Key Findings
    • 2.1.2 Market Dynamics
    • 2.1.3 Market Sizing and Forecast
      • 2.1.3.1 North America Hyperkalemia Market, by Country
        • 2.1.3.1.1 U.S.
  • 2.2 Europe
    • 2.2.1 Key Findings
    • 2.2.2 Market Dynamics
    • 2.2.3 Market Sizing and Forecast
      • 2.2.3.1 Europe Hyperkalemia Market, by Country
        • 2.2.3.1.1 Germany
        • 2.2.3.1.2 U.K.
        • 2.2.3.1.3 France
        • 2.2.3.1.4 Italy
  • 2.3 Asia Pacific
    • 2.3.1 Key Findings
    • 2.3.2 Market Dynamics
    • 2.3.3 Market Sizing and Forecast
      • 2.3.3.1 Asia Pacific Hyperkalemia Market, by Country
        • 2.3.3.1.1 China
        • 2.3.3.1.2 Japan

3. Global Hyperkalemia Market: Competitive Landscape and Company Profiles

  • 3.1 Key Strategies and Development
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Synergistic Activities
    • 3.1.3 Business Expansions and Funding
    • 3.1.4 Product Launches and Approvals
    • 3.1.5 Other Activities
  • 3.2 Company Profiles
    • 3.2.1 Sanofi
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Ardelyx
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 AstraZeneca
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 Vifor Pharma (Zeria Pharmaceutical)
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Eli Lilly and Company
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 Novo Nordisk
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
    • 3.2.7 Zynteglo (Bluebird Bio)
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Top Competitors
      • 3.2.7.4 Target Customers/End-Users
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 Novartis AG
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products / Product Portfolio
      • 3.2.8.3 Top Competitors
      • 3.2.8.4 Target Customers/End-Users
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View

4. Research Methodology

List of Figures

  • Figure: Global Hyperkalemia Market (by Region), $Billion, 2024 and 2035
  • Figure: Global Hyperkalemia Market Key Trends, Analysis

List of Tables

  • Table: Global Hyperkalemia Market Dynamics, Impact Analysis
  • Table: Global Hyperkalemia Market (by Region), $Billion, 2024-2035